TransMedics Group, Inc.
TMDX
$133.81
-$8.12-5.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.24% | 37.68% | 48.21% | 49.83% | 63.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.24% | 37.68% | 48.21% | 49.83% | 63.72% |
| Cost of Revenue | 23.65% | 34.94% | 49.94% | 49.21% | 85.95% |
| Gross Profit | 39.00% | 39.46% | 47.14% | 50.27% | 49.64% |
| SG&A Expenses | 7.87% | 2.78% | 20.64% | 44.06% | 39.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.96% | 18.67% | 37.50% | 47.55% | 55.19% |
| Operating Income | 493.93% | 192.35% | 120.94% | 87.79% | 449.33% |
| Income Before Tax | 442.54% | 197.72% | 115.25% | 80.92% | 115.76% |
| Income Tax Expenses | -4,541.38% | 3,209.76% | 407.14% | 178.57% | 101.92% |
| Earnings from Continuing Operations | 476.83% | 186.26% | 110.56% | 70.11% | 116.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 476.83% | 186.26% | 110.56% | 70.11% | 116.58% |
| EBIT | 493.93% | 192.35% | 120.94% | 87.79% | 449.33% |
| EBITDA | 222.52% | 153.10% | 100.80% | 74.51% | 1,081.82% |
| EPS Basic | 465.34% | 179.55% | 104.57% | 65.26% | 116.18% |
| Normalized Basic EPS | 432.16% | 190.80% | 109.14% | 15.76% | 1,368.52% |
| EPS Diluted | 450.08% | 162.49% | 100.63% | 76.83% | 115.38% |
| Normalized Diluted EPS | 374.87% | 159.11% | 86.97% | 15.76% | 1,277.78% |
| Average Basic Shares Outstanding | 2.01% | 2.39% | 2.93% | 2.90% | 2.54% |
| Average Diluted Shares Outstanding | 14.19% | 14.94% | 15.10% | 3.02% | 9.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |